A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
This study aims to describe current treatment patterns in the real-world setting among
 patients with multiple myeloma who are initiating treatment with (or changing treatment to)
 panobinostat and explore the associations with baseline patient characteristics, healthcare
 resource utilization, and clinical outcomes.
Inclusion Criteria:

 -  Willing and able to provide written informed consent

 -  At least 18 years of age

 -  Clinical diagnosis of multiple myeloma that meets published diagnostic criteria

 -  Initiating panobinostat within 60 days of enrollment

 -  ECOG performance status 0-1

 -  Availability of documentation from the patient's medical records regarding previous
 myeloma treatment, response, and duration of response

 -  Willing and able to complete the PRO questionnaire

 Exclusion Criteria:

 -  Diagnosed with any B-cell malignancy other than myeloma

 -  Estimated life expectancy <6 months

 -  Currently enrolled in any interventional clinical trial at study entry (note: patients
 who enroll in an interventional clinical trial after enrollment may remain in the
 registry)